
AI Analysis Confirms Zabopegdutide Efficacy in MASH Trial
A Phase 2 clinical trial for D&D Pharmatech’s zabopegdutide shows significant liver fibrosis reversal, according to new AI-driven histopathological data. Utilizing HistoIndex’s qFibrosis tool, researchers observed that 81.8% of treated patients achieved meaningful fibrosis stage improvement after 48 weeks, compared to just 18.8% in the placebo group.
























